Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-OncoACP3
- Development stage
- Preclinical
- Lead developer
- RayzeBio
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
18F-OncoACP3 is a small molecule radiopharmaceutical PET imaging agent designed for the detection of metastatic prostate cancer. It targets Acid Phosphatase 3 (ACP3), a novel biomarker that is highly expressed in prostate cancer tissues. The agent consists of the OncoACP3 ligand, originally developed by Philochem and licensed to RayzeBio (a subsidiary of Bristol Myers Squibb), labeled with the positron-emitting radioisotope Fluorine-18. 18F-OncoACP3 is intended to provide high-contrast imaging of tumor lesions with selective uptake and favorable clearance from healthy tissues. It is part of a broader theranostic platform that includes Gallium-68 for diagnostics and Lutetium-177 or Actinium-225 for radioligand therapy.
- Other names
- F-18 OncoACP3F18 OncoACP3F 18 OncoACP3OncoACP3OncoACP-3OncoACP 3
02
Targets
PAP (Prostatic acid phosphatase)
Beyond the preview
Go deeper on 18F-OncoACP3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-OncoACP3.